On November 6, BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS fell 9.95% in After-Hours Trading to $382.32, with turnover of $7.1765 million.
The latest disclosed catalyst tied to the move is a post-results reversal after the company reported strong third-quarter performance and lifted full-year guidance for the third time this year, but the shares gave back earlier gains in after-hours trading.
Previously disclosed figures showed first-nine-month revenue of RMB34.993 billion, up 26.8% year over year, and net profit attributable to shareholders of RMB6.055 billion, up 431.8%. Third-quarter global total revenue reached $1.9 billion. The company raised its full-year revenue outlook to RMB46.3 billion-RMB47.0 billion from RMB44.9 billion-RMB46.2 billion, and lifted total revenue guidance to $6.9 billion-$7.0 billion. Earlier in the day, the company had also benefited from FDA priority review for a Brukinsa combination in first-line mantle cell lymphoma, highlighting continued momentum in its core oncology franchise.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments